Therapy of mental disorders in patients with hematological malignancies

Vybornykh D.E.; Ivanov S.V.; Gemdzhian E.G.; Esina L.V.; Gaponova T.V.

doi:https://doi.org/10.17116/jnevro2024124041127

Vybornykh D.E.

National Medical Research Center for Hematology

ORCID: 0000-0001-7506-4947

Ivanov S.V.

Mental Health Research Center

ORCID: 0000-0001-9532-7150

Gemdzhian E.G.

National Medical Research Center for Hematology

ORCID: 0000-0002-8357-977X

Esina L.V.

National Medical Research Center for Hematology;
Sechenov First Moscow State Medical University

ORCID: 0000-0001-7253-5694

Gaponova T.V.

National Medical Research Center for Hematology

ORCID: 0000-0002-9684-5045

Therapy of mental disorders in patients with hematological malignancies

Authors:

Vybornykh D.E., Ivanov S.V., Gemdzhian E.G., Esina L.V., Gaponova T.V.

More about the authors

Journal: S.S. Korsakov Journal of Neurology and Psychiatry. 2024;124(4): 127‑136

DOI: 10.17116/jnevro2024124041127

Read: 1331 times

Download PDF (RU)

Contact the author

Table of contents

To cite this article:

Vybornykh DE, Ivanov SV, Gemdzhian EG, Esina LV, Gaponova TV. Therapy of mental disorders in patients with hematological malignancies. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;124(4):127‑136. (In Russ.)
https://doi.org/10.17116/jnevro2024124041127

Подписка 2026 Журнал неврологии и психиатрии им. С.С. Корсакова (S.S. Korsakov Journal of Neurology and Psychiatry)

Использование инфографики авторами научных работ

Close metadata

OBJECTIVE

To assess the possibilities of therapy with minimal effective doses (MED) of psychotropic drugs for mental disorders (MD) that manifest during the treatment of hematological malignancies (HM).

MATERIAL AND METHODS

A prospective study was conducted at the National Medical Research Center for Hematology of the Russian Ministry of Health (Moscow), which included 204 (39.4%) men and 314 (60.6%) women (518 patients in total), aged 17 to 83 years (median 45 years), with various HM, in which the manifestation of MD occurred during the treatment of the underlying disease. To minimize the side-effects of psychotropic drugs and given the relatively mild level of MD, psychopharmacotherapy of patients was carried out mainly at MED. The severity of MD, manifested in patients, was assessed by the illness severity scale of the Clinical Global Impression (CGI) scale, and the effectiveness of the treatment was assessed by the improvement scale (CGI-I).

RESULTS

Mainly mild (188, 36%) and moderately pronounced (270, 52%) MD were noted in patients with HM during the treatment of the underlying disease. Severe psychopathological disorders (60, 12%) were observed much less often. Because of psychopharmacotherapy with MED, patients experienced a very significant (97, 19%) and significant improvement (354, 68%) of their mental state, less often the improvement was regarded as minimal (67, 13%). Therefore, almost all patients showed a stable relief of MD; in 87% (95% CI 84—90) of patients, this improvement was significant.

CONCLUSION

The tactics of treatment MD that manifest in patients with HM with MED of psychotropic drugs turned out to be therapeutically effective according to the results of the assessment on CGI scales.

Keywords:

psychopharmacotherapy

minimum effective doses

psychotropic drugs

hematological malignancies

overall clinical impression scale (CGI)

frequency analysis

Authors:

Vybornykh D.E.

National Medical Research Center for Hematology

ORCID: 0000-0001-7506-4947

Ivanov S.V.

Mental Health Research Center

ORCID: 0000-0001-9532-7150

Gemdzhian E.G.

National Medical Research Center for Hematology

ORCID: 0000-0002-8357-977X

Esina L.V.

National Medical Research Center for Hematology;
Sechenov First Moscow State Medical University

ORCID: 0000-0001-7253-5694

Gaponova T.V.

National Medical Research Center for Hematology

ORCID: 0000-0002-9684-5045

Received:

07.07.2023

Accepted:

21.01.2024

Close metadata

References:

Vybornykh DE. Psychohematology. M.: Publishing House «Practical Medicine»; 2014. (In Russ.).
Psychosomatic disorders in clinical practice. Eds. acad. RAS Smulevich A.B. 2nd ed. M.: MEDpress-inform; 2019. (In Russ.).
Ohayon MM, Lader MH. Use of psychotropic medication in the general population of France, Germany, Italy, and the United Kingdom. J Clin Psychiatry. 2002;63(9):817-825. https://doi.org/10.4088/jcp.v63n0912
Yokomichi N, Maeda I, Morita T, et al. Association of Antipsychotic Dose With Survival of Advanced Cancer Patients With Delirium. J Pain Symptom Manage. 2022;64(1):28-36. https://doi.org/10.1016/j.jpainsymman.2022.03.005
Tolmachev AV, Vostokova NV. Development of a registration clinical trial protocol. Remedium. 2015;4:53-57. (In Russ.).
Liu J. Minimum Effective Dose. In Chow S. (ed.). Encyclopedia of Biopharmaceutical Statistics. Taylor & Francis. 2010. https://doi.org/10.1081/E-EBS3
Bangalore S, Shah R, Pappadopulos E, et al. Cardiovascular hazards of insufficient treatment of depression among patients with known cardiovascular disease: a propensity score adjusted analysis. Eur Heart J Qual Care Clin Outcomes. 2018;4(4):258-266. https://doi.org/10.1093/ehjqcco/qcy023
Ilyina NA, Burlakov AV. Schizophrenic nosogenic reactions in patients with cardiovascular pathology. Psihiatrija i Psihofarmakoterapija. 2005;7(3):128-132. (In Russ.).
Samushiya MA, Vecherinina KO. Pathocharacterological disorders in the late postoperative period of coronary artery bypass grafting (clinic and therapy). Psihiatrija i Psihofarmakoterapija. 2005;(4):214-217. (In Russ.).
Ivanov SV, Volel BA, Syrkina EA, et al. A retrospective historical study evaluating the safe use of current antidepressants in cardiology practice. Terapevticheskii Arkhiv. 2017;89(12):34-42. (In Russ.). https://doi.org/10.17116/terarkh2017891234-42
Chamberlain FE, Walsh N, Falkowski J. Chemotherapy for Hodgkin’s lymphoma in a patient receiving clozapine for treatment-resistant schizophrenia: use of the Mental Capacity Act 2005. BJPsych Bull. 2015;39(6):305-307. https://doi.org/10.1192/pb.bp.114.048306
Greenberg DR, Khandwala YS, Lu Y, et al. Disease burden in offspring is associated with changing paternal demographics in the United States. Andrology. 2020;8(2):342-347. https://doi.org/10.1111/andr.12700
Augustin NB, Maroules M. Hyperleukocytosis during clozapine treatment: A rare presentation of B-cell Acute lymphoblastic leukemia. Leuk Res Rep. 2021;15:100253. https://doi.org/10.1016/j.lrr.2021.100253
Leucht S, Samara M, Heres S, et al. Dose equivalents for second-generation antipsychotics: the minimum effective dose method. Schizophr Bull. 2014;40(2):314-326. https://doi.org/10.1093/schbul/sbu001
Vybornykh DE, Ivanov SV, Savchenko VG, Gemdzhian EG. Somatogenic and somatogenically provoked psychoses in diseases of the blood system. Risk factors for the development of somatogenic psychoses in diseases of the blood system. Terapevticheskij Arhiv. 2008;80(7):38-43. (In Russ.).
Vybornykh DE, Zakharov VV, Gemdzhyan EG, et al. Predictors of severe lesions of the central nervous system in the treatment of diseases of the blood system. S.S. Korsakov Journal of Neurology and Psychiatry. 2021;121(11):33-38. (In Russ.). https://doi.org/10.17116/jnevro202112111133
Hyland KA, Nelson AM, Eisel SL, et al. Fatigue Perpetuating Factors as Mediators of Change in a Cognitive Behavioral Intervention for Targeted Therapy-Related Fatigue in Chronic Myeloid Leukemia: A Pilot Study. Ann Behav Med. 2022;56(2):137-145. https://doi.org/10.1093/abm/kaab035
Kayilioğlu H, Kocak U, Kan Karaer D, et al. Association of CYP3A5 Expression and Vincristine Neurotoxicity in Pediatric Malignancies in Turkish Population. J Pediatr Hematol Oncol. 2017;39(6):458-462.
Panneerselvam S, Yesudhas D, Durai P, et al. A Combined Molecular Docking/Dynamics Approach to Probe the Binding Mode of Cancer Drugs with Cytochrome P450 3A4. Molecules. 2015;20(8):14915-14935.
Hedrich WD, Hassan HE, Wang H. Insights into CYP2B6-mediated drug-drug interactions. Acta Pharm Sin B. 2016;6(5):413-425. https://doi.org/10.1016/j.apsb.2016.07.016
Cordova E, Morganti L, Odzak A, et al. Severe hypokalemia due to a possible drug-drug interaction between vinblastine and antiretrovirals in a HIV-infected patient with Hodgkin’s lymphoma. Int J STD AIDS. 2017;956462417703026.
Lewis BC, Korprasertthaworn P, Miners JO. Impaired dacarbazine activation and 7-ethoxyresorufin deethylation in vitro by polymorphic variants of CYP1A1 and CYP1A2 Pharmacogenet. Genomics. 2016;26(10):453-461.
Tulsyan S, Agarwal G, Lal P, et al. Significant role of CYP450 genetic variants in cyclophosphamide based breast cancer treatment outcomes: a multi-analytical strategy. Clin Chim Acta. 2014;434:21-28.
Joerger M. Covariate pharmacokinetic model building in oncology and its potential clinical relevance. AAPS J. 2012;14(1):119-132.
Alonso S, Su M, Jones JW, et al. Human bone marrow niche chemoprotection mediated by cytochrome P450 enzymes. Oncotarget. 2015;6(17):14905-14912.
Wahlang B, Falkner KC, Cave MC, et al. Role of Cytochrome P450 Monooxygenase in Carcinogen and Chemotherapeutic Drug Metabolism. Adv Pharmacol. 2015;74:1-33.
Putkaradze N, Kiss FM, Schmitz D, et al. Biotransformation of prednisone and dexamethasone by cytochrome P450 based systems — Identification of new potential drug candidates. J Biotechnol. 2017;242:101-110. https://doi.org/10.1016/j.jbiotec.2016.12.011
Bachanova V, Shanley R, Malik F, et al. Cytochrome P450 2B6*5 Increases Relapse after Cyclophosphamide-Containing Conditioning and Autologous Transplantation for Lymphoma. Biol Blood Marrow Transplant. 2015;21(5):944-948. https://doi.org/10.1016/j.bbmt.2015.02.001
Quintanilha JCF, de Sousa VM, Visacri MB, et al. Involvement of cytochrome P450 in cisplatin treatment: implications for toxicity. Cancer Chemother Pharmacol. 2017;80(2):223-233.
McGrane IR, Loveland JG, de Leon J. Possible Oxcarbazepine Inductive Effects on Aripiprazole Metabolism: A Case Report. J Pharm Pract. 2017;897190017710523.
Bykov YuV, Bekker RA. Effectiveness of an atypical antipsychotic sulpiride in the therapy of various anxiety disorders and anxiety symptoms present in other disorders (a review of the literature). Psychiatry and Psychopharmacotherapy (P.B. Gannushkin Journal). 2016;18(5):29-37. (In Russ.).
Lisbeth P, Vincent H, Kristof M, et al. Genotype and co-medication dependent CYP2D6 metabolic activity: effects on serum concentrations of aripiprazole, haloperidol, risperidone, paliperidone and zuclopenthixol. Eur J Clin Pharmacol. 2016;72(2):175-184.
Greenblatt DJ, von Moltke LL, Harmatz JS, et al. Alprazolam pharmacokinetics, metabolism, and plasma levels: clinical implications. J Clin Psychiatry. 1993;54(suppl):4-11;discussion 12-14.
Luk S, Atayee RS, Ma JD, et al. Urinary diazepam metabolite distribution in a chronic pain population. J Anal Toxicol. 2014;38(3):135-142.
Ivashchenko DV, Rudik AV, Poloznikov AA, et al. Which cytochrome P450 metabolizes phenazepam? Step by step in silico, in vitro, and in vivo studies. Drug Metab Pers Ther. 2018;33(2):65-73. https://doi.org/10.1515/dmpt-2017-0036
Seree EJ, Pisano PJ, Placidi M, et al. Identification of the human and animal hepatic cytochromes P450 involved in clonazepam metabolism. Fundam Clin Pharmacol. 1993;7(2):69-75. https://doi.org/10.1111/j.1472-8206.1993.tb00219.x
Konishi K, Fukami T, Gotoh S, et al. Identification of enzymes responsible for nitrazepam metabolism and toxicity in human. Biochem Pharmacol. 2017;140:150-160. https://doi.org/10.1016/j.bcp.2017.06.114
Hamelin BA, Bouayad A, Drolet B, et al. In vitro characterization of cytochrome P450 2D6 inhibition by classic histamine H1 receptor antagonists. Drug Metab Dispos. 1998;26(6):536-539.
Brøsen K. Some aspects of genetic polymorphism in the biotransformation of antidepressants. Therapie. 2004;59(1):5-12. https://doi.org/10.2515/therapie:2004003
He Q, Yuan Z, Liu Y, et al. Correlation between cytochrome P450 2C19 genetic polymorphism and treatment response to escitalopram in panic disorder. Pharmacogenet Genomics. 2017;27(8):279-284.
Chang M, Tybring G, Dahl ML, et al. Impact of cytochrome P450 2C19 polymorphisms on citalopram/escitalopram exposure: a systematic review and meta-analysis. Clin Pharmacokinet. 2014;53(9):801-811. https://doi.org/10.1007/s40262-014-0162-1
Yuce-Artun N, Baskak B, Ozel-Kizil ET, et al. Influence of CYP2B6 and CYP2C19 polymorphisms on sertraline metabolism in major depression patients. Int J Clin Pharm. 2016;38(2):388-394.
Kowalewski C, Haen E, Hiemke C, et al. Cytochrome P450-mediated inhibition of venlafaxine metabolism by trimipramine. Int Clin Psychopharmacol. 2019;34(5):241-246. https://doi.org/10.1097/YIC.0000000000000268
Irarrázaval OME, Gaete GL. Antidepressants agents in breast cancer patients using tamoxifen: review of basic and clinical evidence. Rev Med Chil. 2016;144(10):1326-1335.
Saiz-Rodríguez M, Ochoa D, Belmonte C, et al. Polymorphisms in CYP1A2, CYP2C9 and ABCB1 affect agomelatine pharmacokinetics. J Psychopharmacol. 2019;33(4):522-531. https://doi.org/10.1177/0269881119827959
Tong S, Guo J, Song H, et al. Effect of ademetionine on cytochrome P450 isoforms activity in rats. Int J Clin Exp Med. 2015;8(6):9716-9722.
Murphy MP, Beaman ME, Clark LS, et al. Prospective CYP2D6 genotyping as an exclusion criterion for enrollment of a phase III clinical trial. Pharmacogenetics. 2000;10(7):583-590. https://doi.org/10.1097/00008571-200010000-00002
Giri P, Naidu S, Patel N, et al. Evaluation of In Vitro Cytochrome P450 Inhibition and In Vitro Fate of Structurally Diverse N-Oxide Metabolites: Case Studies with Clozapine, Levofloxacin, Roflumilast, Voriconazole and Zopiclone. Eur J Drug Metab Pharmacokinet. 2017;42(4):677-688.